Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide ... from Novartis and Clarity Pharma; consulting fees for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback